Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.64 |
| ▸ | SNCA | P37840 | 4/20 | 0.64 |
| ▸ | BACE1 | P56817 | 2/20 | 0.60 |
| ▸ | HTR6 | P50406 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14207388 | 0.88 | NPC1 (0.67) | APPSNCABACE1HTR6NPC1 | |
| SCHEMBL8685570 | 0.85 | CYP2A6 (0.53) | APPSNCABACE1HTR6NPC1 | |
| SCHEMBL8388266 | 0.82 | BACE1 (0.74) | APPSNCABACE1HTR6NPC1 | |
| SCHEMBL18003394 | 0.82 | KCNQ3 (0.47) | APPSNCABACE1HTR6CYP2A6 | |
| SCHEMBL18002643 | 0.82 | MAPT (0.50) | APPSNCABACE1CYP2A6 | |
| SCHEMBL18002299 | 0.81 | HTR6 (0.51) | APPSNCABACE1HTR6NPC1 | |
| SCHEMBL18002567 | 0.80 | FGFR1 (0.47) | APPSNCABACE1HTR6NPC1 | |
| SCHEMBL9057914 | 0.80 | APP (0.65) | APPSNCABACE1HTR6NPC1 | |
| SCHEMBL9057916 | 0.80 | APP (0.65) | APPSNCABACE1HTR6NPC1 | |
| SCHEMBL18003266 | 0.79 | CYP2A6 (0.46) | APPSNCABACE1HTR6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003169-A | GPR40 receptor agonist, method for preparing same, and pharmaceutical composition containing same as active ingredient | 株式会社LG化学 | 2019-07-12 | — | — | CN | disclosed |
| EP-3323816-B1 | NOVEL PYRAZOLE DERIVATIVE | GREEN TECHNOLOGY CO LTD (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-9988379-B2 | GPR40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent | LG CHEM, LTD. (KR) | 2018-06-05 | — | — | US | disclosed |
| EP-3323816-A1 | NOVEL PYRAZOLE DERIVATIVE | Green Tech Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
| CN-103717588-B | Pyrazole derivatives | 绿色科技株式会社 | 2016-08-03 | — | — | CN | disclosed |
| US-9399635-B2 | Pyrazole derivative | GREEN TECH CO., LTD. (JP) | 2016-07-26 | — | — | US | disclosed |
| US-20150291584-A1 | GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG CHEM, LTD. (KR) | 2015-10-15 | — | — | US | disclosed |
| EP-2917180-A1 | GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG Life Sciences Ltd. (KR) | 2015-09-16 | — | — | EP | disclosed |
| CN-104837816-A | GPR40 receptor agonist, method for preparing same, and pharmaceutical composition containing same as active ingredient | LG LIFE SCIENCES LTD | 2015-08-12 | — | — | CN | disclosed |
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | disclosed |
| WO-2014073904-A1 | GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2014-05-15 | — | — | WO | disclosed |
| US-20140088029-A1 | NOVEL PYRAZOLE DERIVATIVE | PHARMA EIGHT CO., LTD. (JP) | 2014-03-27 | — | — | US | disclosed |
| EP-2698368-A1 | NOVEL PYRAZOLE DERIVATIVE | Pharma Eight Co. Ltd (JP) | 2014-02-19 | — | — | EP | disclosed |
| CN-101558038-B | Curcumin derivative | TOKYO INST TECH | 2013-05-01 | — | — | CN | disclosed |
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2123637-A1 | NOVEL CURCUMIN DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-11-25 | — | — | EP | disclosed |
| CN-101558038-A | Novel curcumin derivative | TOKYO INST TECH (JP) | 2009-10-14 | — | — | CN | disclosed |
| US-5811439-A | ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION; ANTILEPEMIC AGENTS | SENGA PHARMACEUTICAL LABORATORY INC. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0780389-A1 | Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them | TOBISHI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | APP 2/4885SNCA 285/4885BACE1 1/4885 |
| US-20150291584-A1 | GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | GPR119, GPR65, GPR55 | APP 1356/4885SNCA 4485/4885BACE1 2646/4885 |
| US-20140088029-A1 | NOVEL PYRAZOLE DERIVATIVE | PSEN2, MAPT, PSEN1 | APP 4/4885SNCA 249/4885BACE1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.